AstraZeneca Pharmaceuticals LP settled their case against Biovail Corp. over the production of a generic form of AstraZeneca’s bipolar disorder and schizophrenia drug, Seroquel®. Biovail consented not to commercially sell their generic version of the drug until the two patents at issue have expired. The judge also granted AstraZeneca access to some of Biovail’s confidential information for use in their related cases against other pharmaceutical companies who wish to market a generic version of Seroquel®. AstraZeneca is represented by Finnegan.
Award/Ranking
Finnegan Receives Tier 1 Benchmark Litigation Rankings; Nine Attorneys Named Litigation Stars
October 5, 2023
Press Release
Finnegan Earns Law360’s Practice Group of the Year for Intellectual Property
January 18, 2023
Justin A. Hendrix
Finnegan Recognized as Leader in Intellectual Property Litigation at 2013 LMG Life Sciences Awards
September 26, 2013
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.